AWA
CRSP icon

Arkadios Wealth Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Arkadios Wealth Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$448K Sell
9,416
-1
-0% -$53 0.01% 1170
2025
Q4 		$494K Sell
9,417
-951
-9% -$57K 0.01% 1021
2025
Q3 		$672K Sell
10,368
-247
-2% -$14.2K 0.02% 817
2025
Q2 		$516K Sell
10,615
-623
-6% -$24.1K 0.02% 828
2025
Q1 		$382K Sell
11,238
-923
-8% -$39.1K 0.01% 809
2024
Q4 		$479K Buy
12,161
+866
+8% +$40.9K 0.03% 560
2024
Q3 		$531K Buy
11,295
+524
+5% +$26.6K 0.03% 519
2024
Q2 		$582K Sell
10,771
-96
-0.9% -$5.55K 0.04% 423
2024
Q1 		$741K Sell
10,867
-158
-1% -$11.3K 0.06% 301
2023
Q4 		$690K Sell
11,025
-235
-2% -$13K 0.06% 295
2023
Q3 		$511K Buy
11,260
+130
+1% +$6.71K 0.05% 335
2023
Q2 		$625K Sell
11,130
-558
-5% -$31.7K 0.07% 259
2023
Q1 		$529K Sell
11,688
-44
-0.4% -$2.14K 0.06% 289
2022
Q4 		$477K Sell
11,732
-1,302
-10% -$69.1K 0.06% 292
2022
Q3 		$852K Sell
13,034
-216
-2% -$15.7K 0.13% 184
2022
Q2 		$805K Buy
13,250
+26
+0.2% +$1.53K 0.12% 203
2022
Q1 		$830K Buy
13,224
+404
+3% +$25.4K 0.11% 216
2021
Q4 		$971K Buy
12,820
+12,650
+7,441% +$1.11M 0.13% 185
2021
Q3 		$19K Hold
170
– – ﹤0.01% 1228
2021
Q2 		$27K Buy
+170
New +$20.7K ﹤0.01% 1156
2021
Q1 		– Sell
-34
Closed -$5K – 1654
2020
Q4 		$5K Buy
34
+14
+70% +$1.66K ﹤0.01% 1109
2020
Q3 		$2.2K Hold
20
– – ﹤0.01% 933
2020
Q2 		$1.82K Hold
20
– – ﹤0.01% 874
2020
Q1 		$848 Buy
+20
New +$1.03K ﹤0.01% 979

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Arkadios Wealth Advisors's CRSP Position: Q1 2026 in Review

Arkadios Wealth Advisors reduced its CRISPR Therapeutics (CRSP) stake by 0.01% in Q1 2026, selling an estimated $53 and leaving 9,416 shares worth $448K. The position accounts for 0.01% of the portfolio, ranked #1170.

Arkadios Wealth Advisors first reported a position in CRSP in Q1 2020 and has held it in 24 quarters since. The position peaked at $971K in Q4 2021. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Arkadios Wealth Advisors held 9,416 shares of CRISPR Therapeutics worth $448K as of Q1 2026.
  • Arkadios Wealth Advisors sold 1 CRISPR Therapeutics share in Q1 2026, an estimated $53.
  • CRISPR Therapeutics made up 0.01% of Arkadios Wealth Advisors's portfolio in Q1 2026, its #1170 holding.
  • Arkadios Wealth Advisors first reported a position in CRISPR Therapeutics in Q1 2020 and has held it in 24 quarters since.
  • Arkadios Wealth Advisors's CRISPR Therapeutics position peaked at $971K in Q4 2021.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Arkadios Wealth Advisors's 13F filing for Q1 2026, filed 18 May 2026.